CELC May 2024 20.000 put
| Previous Close | 1.9500 |
| Open | 1.9500 |
| Bid | 0.6500 |
| Ask | 4.4000 |
| Strike | 20.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 1.9500 - 1.9500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 81 |
GlobeNewswireCelcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer $177.7 million in cash, cash equivalents and short-term investments expected to provide runway into the first half of 2026 Management to host webcast and conference call today, May 15, 2024, at
- GlobeNewswire
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To partici
- GlobeNewswire
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast w
